Overview

Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

Status:
Terminated

Trial end date:
2011-03-01

Target enrollment:

Participant gender:

Summary

This randomized phase II trial will compare the efficacy and toxicity of Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin in patients with pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Hellenic Oncology Research Group

Collaborator:

University Hospital of Crete

Treatments:

Erlotinib Hydrochloride
Gemcitabine
Oxaliplatin